Commercial validation is still the binding risk. The core question is not whether
QCi has interesting assets; it is whether those assets become repeatable, better-utilized revenue with improving
gross margins. The balance sheet lowers financing risk, but valuation risk stays high because the stock already discounts a platform outcome. Acquisition integration, export controls, customer concentration, and future
dilution can all interrupt the path from promising
photonics owner to durable infrastructure supplier.